CHA Vaccine Research Institute (KOSDAQ:261780)

Market Cap	97.12B +16.8%
Revenue (ttm)	158.62M -57.2%
Net Income	-16.04B
EPS	-597.00
Shares Out	26.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,711,733
Average Volume	9,105,565
Open	3,895.00
Previous Close	3,735.00
Day's Range	3,420.00 - 4,030.00
52-Week Range	2,280.00 - 6,720.00
Beta	0.58
RSI	50.06
Earnings Date	n/a

About KOSDAQ:261780

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer va...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 261780

Financial Performance

In 2025, KOSDAQ:261780's revenue was 158.62 million, a decrease of -57.21% compared to the previous year's 370.66 million. Losses were -16.04 billion, 58.3% more than in 2024.